Tirzepatide Explored for Menopausal Hot Flashes and Biological Aging in Obese Women

Menopause often brings challenging vasomotor symptoms like hot flashes, significantly impacting quality of life for many women. Obesity can exacerbate these symptoms and is also linked to accelerated biological aging, presenting a dual health challenge. While tirzepatide is well-established for weight loss and metabolic benefits, its potential impact on menopausal symptoms and biological aging markers in obese post-menopausal women is currently an unexplored knowledge gap.

As this is a pilot study that is currently recruiting participants (NCT07218445), specific results regarding the effects of tirzepatide on menopausal vasomotor symptoms or biological aging markers are not yet available. The study aims to determine if tirzepatide can significantly reduce the frequency and severity of hot flashes, which are common vasomotor symptoms in post-menopausal women. Researchers will also assess its impact on various biological aging markers, such as epigenetic clocks, to see if it can slow or reverse aspects of cellular aging. The study will collect data on hot flash frequency, intensity, and duration, expecting to see a statistically significant decrease in the tirzepatide group compared to placebo. Additionally, blood samples will be analyzed for biomarkers of biological aging, with an anticipated positive shift in age-related metrics. The primary objective is to establish preliminary efficacy data, looking for a quantifiable reduction in symptom burden and measurable improvements in biological age indicators, to support the rationale for larger, definitive clinical trials.